40
Participants
Start Date
December 22, 2021
Primary Completion Date
July 31, 2026
Study Completion Date
January 31, 2029
Fasudil (WP-0512)
Oral fasudil up to 180 mg/day
Fasudil (WP-0512)
Oral fasudil up to 300 mg/day
Hospital for Special Surgery, New York
Lakes Research, Miami Lakes
University of South Florida, Tampa
University of Kentucky, Lexington
Northwestern University, Chicago
Cox Medical Center, Springfield
University of Colorado, Aurora
National Jewish Health, Denver
Neuromuscular Research Center, Phoenix
Macquarie University Hospital, Sydney
Royal Brisbane and Women's Hospital, Brisbane
Calvary Health Bethlehem Hospital, Melbourne
Lead Sponsor
Woolsey Pharmaceuticals
INDUSTRY